MATSUZAKI Juntaro

写真a

Affiliation

Faculty of Pharmacy, Department of Pharmacy Division of Pharmacotherapeutics (Shiba-Kyoritsu)

Position

Associate Professor

Related Websites

External Links

 

Research Areas 【 Display / hide

  • Life Science / Tumor diagnostics and therapeutics

  • Life Science / Gastroenterology

Research Keywords 【 Display / hide

  • cancer

  • microRNA

  • extracellular RNA

 

Books 【 Display / hide

  • がん早期診断. テクノロジーロードマップ2019-2028 医療・健康・食農編

    松﨑潤太郎, 落谷孝広, 日経BP, 2019

  • 血中マイクロRNAを用いた膵がん診断の展望. 早期発見・予防に向けた次世代がん検査技術の最前線

    松﨑潤太郎, シーエムシー出版, 2019

  • 胃・十二指腸潰瘍. 看護基礎教育テキスト ナーシング・グラフィカ「疾患と看護シリーズ」『3 消化器疾患と看護』

    松﨑潤太郎, 鈴木秀和, メディカ出版, 2019

  • エクソソームに着目した新しい診断技術の開発. 早期発見・低侵襲で見つけ出す疾患・病態検査・診断法の開発 ~がん、認知症、感染症、難病、糖尿病、リウマチ、希少疾患~

    松﨑潤太郎, 落谷孝広, 技術情報協会, 2017

  • がん早期診断. テクノロジーロードマップ2017-2026 医療・健康・食農編

    松﨑潤太郎, 落谷孝広, 日経BP, 2017

display all >>

Papers 【 Display / hide

  • Development of plasma ghrelin level as a novel marker for gastric mucosal atrophy after Helicobacter pylori eradication

    H Mori, H Suzuki, J Matsuzaki, K Kameyama, K Igarashi, T Masaoka, ...

    Annals of Medicine 54 (1), 170-180 (Annals of Medicine)  54 ( 1 ) 170 - 180 2022

    Research paper (scientific journal), Accepted

     View Summary

    Background and aim: The severity of atrophic gastritis is significantly associated with the risk of gastric cancer. Although the current gold standard for assessing the gastric cancer risk is esophagogastroduodenoscopy with a pathological examination, the development of less-invasive biomarkers is warranted for efficient risk stratification of gastric cancer. Serum pepsinogens (PGs) are biomarkers used to predict the extent of gastric mucosal atrophy; however, they are not an accurate reflection of gastric mucosal atrophy after Helicobacter pylori eradication. The present study was conducted to investigate the usefulness of plasma ghrelin levels as a marker for gastric mucosal atrophy, and as a risk stratification marker for gastric cancer, even after H. pylori eradication. Methods: Patients who received H. pylori eradication treatment were enrolled in the study. The severity of gastric mucosal atrophy was evaluated both endoscopically and histologically. Serum pepsinogen and plasma ghrelin levels were measured before and at 1, 12, 24, and 48 weeks after treatment. The study was approved by the Research Ethics Committee of the Keio University School of Medicine (no. 20140102; 8 July 2014). Results: Eighteen patients completed the study protocol. Total and acyl plasma ghrelin levels demonstrated no significant change from before treatment to 48 weeks after eradication; however, there was a significant difference between open-type and closed-type atrophic gastritis. The PG I/II ratio increased significantly from 48 weeks after H. pylori eradication. The severity of the histological intestinal metaplasia scores correlated inversely with plasma total ghrelin levels from before to 48 weeks after H. pylori eradication. Conclusion: Plasma levels of ghrelin correlate well with the level of gastric mucosal atrophy, even after H. pylori eradication.KEY MESSAGES Ghrelin plasma levels are associated with the progression of endoscopic atrophic gastritis, even at 48 weeks after H. pylori eradication. Ghrelin plasma levels are also associated with increased severity of histological intestinal metaplasia 48 weeks after H. pylori eradication. Pepsinogen I/II ratios increased immediately after H. pylori eradication and are inappropriate for assessing atrophic gastritis after H. pylori eradication.

  • Extracellular microRNA profiling for prognostic prediction in patients with high‐grade serous ovarian carcinoma

    Kosuke Yoshida and Akira Yokoi and Juntaro Matsuzaki and Tomoyasu Kato and Takahiro Ochiya and Hiroaki Kajiyama and Yusuke Yamamoto

    Cancer Science (Wiley)  112 ( 12 ) 4977 - 4986 2021.10

    Research paper (scientific journal), Accepted

     View Summary

    High-grade serous ovarian carcinoma is a leading cause of death in female patients worldwide. MicroRNAs (miRNAs) are stable noncoding RNAs in the peripheral blood that reflect a patient’s condition, and therefore, they have received substantial attention as noninvasive biomarkers in various diseases. We previously reported the usefulness of serum miRNAs as diagnostic biomarkers. Here, we investigated the prognostic impact of the serum miRNA profile. We used the GSE106817 dataset, which included preoperative miRNA profiles of patients with ovarian malignancies. Excluding patients with other malignancy or insufficient prognostic information, we included 175 patients with high-grade serous ovarian carcinoma. All patients except four underwent surgery and received chemotherapy as initial treatment. The median follow-up period was 54.6 months (range, 3.5-144.1 months). Univariate Cox regression analysis revealed that higher levels of miR-187-5p and miR-6870-5p were associated with both poorer progression-free survival (PFS) and overall survival (OS), and miR-1908-5p, miR-6727-5p, and miR-6850-5p were poor prognostic indicators of PFS. The OS and PFS prognostic indices were then calculated using the expression values of three prognostic miRNAs. Multivariate Cox regression analysis showed that both indices were significantly independent poor prognostic factors (hazard ratio for OS and PFS, 2.343 [P =.015] and 2.357 [P =.005], respectively). In conclusion, circulating miRNA profiles can potentially provide information to predict the prognosis of patients with high-grade serous ovarian carcinoma. Therefore, there is a strong demand for early clinical application of circulating miRNAs as noninvasive biomarkers.

  • Challenges for Better Diagnosis and Management of Pancreatic and Biliary Tract Cancers Focusing on Blood Biomarkers: A Systematic Review

    H Tominaga, J Matsuzaki, C Oikawa, K Toyoshima, H Manabe, E Ozawa, ...

    Cancers 13 (16), 4220 (Cancers)  13 ( 16 )  2021.08

    Research paper (scientific journal), Accepted

     View Summary

    Background: pancreatic cancer (PCa) and biliary tract cancer (BTC) are cancers with a poor prognosis and few effective treatments. One of the reasons for this is late detection. Many researchers are tackling to develop non-invasive biomarkers for cancer, but few are specific for PCa or BTC. In addition, genetic abnormalities occur in cancer tissues, which ultimately affect the expression of various molecules. Therefore, it is important to identify molecules that are altered in PCa and BTC. For this systematic review, a systematic review of Medline and Embase to select biomarker studies of PCa and BTC patients was conducted. Results: after reviewing 72 studies, 79 biomarker candidates were identified, including 22 nucleic acids, 43 proteins, and 14 immune cell types. Of the 72 studies, 61 examined PCa, and 11 examined BTC. Conclusion: PCa and BTC are characterized by nucleic acid, protein, and immune cell profiles that are markedly different from those of healthy subjects. These altered molecules and cell subsets may serve as cancer-specific biomarkers, particularly in blood. Further studies are needed to better understand the diagnosis and prognosis of PCa and BTC.

  • Early prediction of COVID-19 severity using extracellular vesicle COPB2.

    Fujita Y, Hoshina T, Matsuzaki J, Yoshioka Y, Kadota T, Hosaka Y, Fujimoto S, Kawamoto H, Watanabe N, Sawaki K, Sakamoto Y, Miyajima M, Lee K, Nakaharai K, Horino T, Nakagawa R, Araya J, Miyato M, Yoshida M, Kuwano K, Ochiya T

    Journal of extracellular vesicles (Journal of Extracellular Vesicles)  10 ( 8 ) e12092 2021.06

    Research paper (scientific journal), Accepted

     View Summary

    The clinical manifestations of COVID-19 vary broadly, ranging from asymptomatic infection to acute respiratory failure and death. But the predictive biomarkers for characterizing the variability are still lacking. Since emerging evidence indicates that extracellular vesicles (EVs) and extracellular RNAs (exRNAs) are functionally involved in a number of pathological processes, we hypothesize that these extracellular components may be key determinants and/or predictors of COVID-19 severity. To test our hypothesis, we collected serum samples from 31 patients with mild COVID-19 symptoms at the time of their admission for discovery cohort. After symptomatic treatment without corticosteroids, 9 of the 31 patients developed severe/critical COVID-19 symptoms. We analyzed EV protein and exRNA profiles to look for correlations between these profiles and COVID-19 severity. Strikingly, we identified three distinct groups of markers (antiviral response-related EV proteins, coagulation-related markers, and liver damage-related exRNAs) with the potential to serve as early predictive biomarkers for COVID-19 severity. As the best predictive marker, EV COPB2 protein, a subunit of the Golgi coatomer complex, exhibited significantly higher abundance in patients remained mild than developed severe/critical COVID-19 and healthy controls in discovery cohort (AUC 1.00 (95% CI: 1.00-1.00)). The validation set included 40 COVID-19 patients and 39 healthy controls, and showed exactly the same trend between the three groups with excellent predictive value (AUC 0.85 (95% CI: 0.73-0.97)). These findings highlight the potential of EV COPB2 expression for patient stratification and for making early clinical decisions about strategies for COVID-19 therapy.

  • A novel combination of serum microRNAs for the detection of early gastric cancer

    S Abe, J Matsuzaki, K Sudo, I Oda, H Katai, K Kato, S Takizawa, ...

    Gastric Cancer, 1-9 (Gastric Cancer)  24 ( 4 ) 835 - 843 2021.03

    Research paper (scientific journal), Lead author, Accepted

     View Summary

    Background: The aim of this study was to identify serum miRNAs that discriminate early gastric cancer (EGC) samples from non-cancer controls using a large cohort. Methods: This retrospective case–control study included 1417 serum samples from patients with EGC (seen at the National Cancer Center Hospital in Tokyo between 2008 and 2012) and 1417 age- and gender-matched non-cancer controls. The samples were randomly assigned to discovery and validation sets and the miRNA expression profiles of whole serum samples were comprehensively evaluated using a highly sensitive DNA chip (3D-Gene ) designed to detect 2565 miRNA sequences. Diagnostic models were constructed using the levels of several miRNAs in the discovery set, and the diagnostic performance of the model was evaluated in the validation set. Results: The discovery set consisted of 708 samples from EGC patients and 709 samples from non-cancer controls, and the validation set consisted of 709 samples from EGC patients and 708 samples from non-cancer controls. The diagnostic EGC index was constructed using four miRNAs (miR-4257, miR-6785-5p, miR-187-5p, and miR-5739). In the discovery set, a receiver operating characteristic curve analysis of the EGC index revealed that the area under the curve (AUC) was 0.996 with a sensitivity of 0.983 and a specificity of 0.977. In the validation set, the AUC for the EGC index was 0.998 with a sensitivity of 0.996 and a specificity of 0.953. Conclusions: A novel combination of four serum miRNAs could be a useful non-invasive diagnostic biomarker to detect EGC with high accuracy. A multicenter prospective study is ongoing to confirm the present observations. ®

display all >>

Reviews, Commentaries, etc. 【 Display / hide

  • セリバスタチンのヒト肝内胆管がん(IHCC)抑制作用に関する検討

    富永 皓斗, 松崎 潤太郎, 齋藤 義正, 櫻井 美帆, 木村 真規, 村松 俊英

    日本消化器病学会雑誌 ((一財)日本消化器病学会)  118 ( 臨増大会 ) A707 - A707 2021.10

    ISSN  0446-6586

  • アルツハイマー型認知症におけるテプレノンの無作為化プラセボ対照二重盲検比較試験

    横山 俊一, 吉永 拓真, 松崎 潤太郎, 鈴木 秀和

    Dementia Japan ((一社)日本認知症学会)  35 ( 4 ) 619 - 619 2021.10

    ISSN  1342-646X

  • 卵巣漿液性がん患者に対する血清中マイクロRNAの予後予測バイオマーカーとしての意義

    吉田 康将, 横井 暁, 松崎 潤太郎, 加藤 友康, 落谷 孝広, 梶山 広明, 山本 雄介

    日本癌学会総会記事 ((一社)日本癌学会)  80回   [P21 - 2 2021.09

    ISSN  0546-0476

  • スタチン製剤の胆管がん抑制作用に関する検討

    富永 皓斗, 櫻井 美帆, 齋藤 義正, 松崎 潤太郎, 木村 真規, 村松 俊英

    日本癌学会総会記事 ((一社)日本癌学会)  80回   [P14 - 5 2021.09

    ISSN  0546-0476

  • Helicobacter pylori感染症診療のための「基礎」知識

    松崎 潤太郎

    日本ヘリコバクター学会学術集会プログラム・抄録集 ((一社)日本ヘリコバクター学会)  27回   152 - 152 2021.09

display all >>

Presentations 【 Display / hide

  • Therapeutic potential of chemically induced liver progenitor cells for liver fibrosis

    International Session (Symposium)2. “Treatment and research for liver fibrosis - Current and future perspectives” 第29回日本消化器関連学会週間, 

    2021.11

  • Unraveling tumor diversity by microRNA: possibilities and limits

    International Session 3 “Epitranscriptome and tumor heterogeneity” 第80回日本癌学会学術総会, 

    2021.09

  • いつ出るの?血中マイクロRNA診断

    第28回日本がん予防学会総会 ランチョンセミナー3, 

    2021.09

  • H. pylori除菌後ディスペプシアの治療戦略

    新規向け認定講習会.第27回日本ヘリコバクター学会, 

    2021.09

  • 血中miRNA診断技術開発の現状と未来

    第41回日本分子腫瘍マーカー研究会, 

    2021.09

display all >>

Research Projects of Competitive Funds, etc. 【 Display / hide

  • CRISPR-Cas9 based screening for essential tumor suppressors in liver carcinogenesis

    2017.06
    -
    2020.03

    National Cancer Center Japan, Yamamoto Yusuke, Grant-in-Aid for Challenging Research (Exploratory), No Setting

     View Summary

    A large number of research projects identified genetic mutations in the process of carcinogenesis, and there have been some useful findings of studies using cancer cell lines. With next generation sequencing, genetic variants in a variety of cancers have been identified and shown to have an impact on carcinogenesis; however, it is still unclear how the mutations essentially influenced the carcinogenesis and their metastatic potential. In this research project, we introduced and quantitatively analyzed the contribution of genetic mutations involved in the carcinogenic process by CRISPR-Cas9, in order to knockout the tumor suppressor genes in primary epithelial cells, and examined the effect of each gene on carcinogenesis. Also, we tried to recapitulate the multi-step carcinogenesis in vitro. This study enables us to accurately reflect and reproduce genomic aberrations in normal cells, and to achieve validation of the actual function of driver gene mutations.

  • Identification of circulating microRNAs for the detection of early stage pancreatic cancer

    2017.04
    -
    2020.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), Principal investigator

     View Summary

    本研究は、初代分離培養した膵外分泌細胞に対して低分子化合物を曝露させ、in vitroでパーシャルリプログラミングを行って膵前駆細胞を樹立し、この細胞に胆汁酸によるストレス刺激を与えることで膵発がん初期の環境をin vitroでモデル化し、膵発がん超初期のバイオマーカーとなるmicroRNAの同定を試みるものである。我々はラットおよびマウスの膵外分泌細胞を用いて、特定の低分子化合物のコンビネーションが膵前駆細胞を誘導することを見出したが、一方で誘導された膵前駆細胞の性能を、Pdx1やNkx6.1といったマーカー分子で評価したところ、実験ロットによって均質でないことを見出した。そこでsingle cell sortingによって、膵前駆細胞としてより機能的に優れた細胞のクローン化を試み、これに成功した。驚くべきことに、この膵前駆細胞は特定の培養環境下においてインスリンを分泌する細胞にも分化し得た。また膵外分泌細胞よりDBAレクチンを用いて分取した膵管上皮細胞が膵前駆細胞の由来細胞であることも見出した。
    機能的に優れた膵前駆細胞のクローニングに成功した。この細胞に胆汁酸を曝露した際に濃度依存的に変動する細胞内/細胞外マイクロRNAのマイクロアレイ解析も完了し、データ解析を進めている。
    胆汁酸曝露により変動するマイクロRNA候補を同定し、すでに完成しているヒト血清マイクロRNAデータベースと照合することにより、膵がん早期診断マーカーとしてのポテンシャルに優れたマイクロRNAを絞り込む。胆汁酸曝露によるマイクロRNA発現調節機序を解析する。

  • Generation of hepatic progenitor cells from human hepatocytes using small molecules

    2016.04
    -
    2018.03

    National Cancer Center Japan, KATSUDA Takeshi, OCHIYA Takahiro, MATSUZAKI Juntaro, SAITO Yoshimasa, TAKEUCHI Atsuko, Grant-in-Aid for Young Scientists (B), No Setting

     View Summary

    Using small molecule inhibitors, we recently reported that rodent mature hepatocytes can be reprogrammed into progenitor-like phenotype with repopulative capacity. In this study, using the same strategy, we demonstrated that hepatic progenitor cells can be induced from human infant hepatocytes. These cells, named human chemically induced progenitors (hCLiPs), exhibited significant repopulative capacity in injured mouse livers following transplantation, and contributed to reconstruction of the normal liver architecture. We also found that hCLiPs can be redifferentiated into mature hepatocytes in vitro with hepatic inducible factors. These redifferentiated cells can be induced to exhibit cytochrome P450 (CYP) enzymatic activities in response to the CYP inducing molecules with the efficiency comparable with that of primary hepatocytes. Thus, this study contributes to progress in the field of liver cell transplantation therapy and pharmacological research field.

  • Interaction of miR-221/222 and adipocytokine signaling in esophageal adenocarcinoma

    2014.04
    -
    2016.03

    Keio University, Matsuzaki Juntaro, TSUGAWA Hitoshi, SUZUKI Hidekazu, Grant-in-Aid for Young Scientists (B), No Setting

     View Summary

    Esophageal adenocarcinoma, which is rapidly increasing in Western countries, is one of the complications of gastroesophageal reflux disease. Bile reflux and central obesity are major risk factors for esophageal adenocarcinoma. In general, plasma adiponectin levels are decreased through the progression of central obesity. We had reported that bile acids contribute to carcinogenesis through the activation of nuclear bile acid receptor (FXR) and the enhancement of miR-221/222. Herein, we identified that miR-221/222 enhance the expression of COX-2 in esophageal epithelial cells. On the other hand, COX-2 expression was suppressed during exposure to adiponectin receptor agonist. These results suggest adiponectin receptor agonist might work as a chemopreventive agent for esophageal adenocarcinoma among high-risk individuals with central obesity.

  • 食道腺がん治療標的としてのCDX2分解系とmiR-221/222の重要性の解明

    2011.04
    -
    2012.03

    Keio University, Grant-in-Aid for Young Scientists (B), No Setting

Awards 【 Display / hide

  • 日本癌学会奨励賞

    2020

    Type of Award: Award from Japanese society, conference, symposium, etc.

  • the 15th Korea-Japan Joint Symposium on Helicobacter infection Young Investigator Award

    2018

    Type of Award: Award from international society, conference, symposium, etc.

  • United European Gastroenterology Week (UEGW) 2016 Poster of Excellence

    2016

    Type of Award: Award from international society, conference, symposium, etc.

  • 第18回日本神経消化器病学会・第6回IBS研究会・第84回消化器心身医学研究会・第10回機能性ディスペプシア研究会合同学術集会 並木賞

    2016

    Type of Award: Award from Japanese society, conference, symposium, etc.

  • 4th Biennial Congress of Asian Neurogastroenterology & Motility Association (ANMA) Best Poster Presentation Award

    2015

    Type of Award: Award from international society, conference, symposium, etc.

display all >>

 

Courses Taught 【 Display / hide

  • STUDY OF MAJOR FIELD: (PHARMACOTHERAPEUTICS)

    2022

  • SEMINAR:(PHARMACOTHERAPEUTICS)

    2022

  • RESEARCH FOR BACHELOR'S THESIS 1

    2022

  • PRE-CLINICAL TRAINING FOR HOSPITAL & COMMUNITY PHARMACY

    2022

  • PHYSICAL ASSESSMENT AND DIAGNOSTIC IMAGING

    2022

display all >>

 

Committee Experiences 【 Display / hide

  • 2019
    -
    Present

    日本微小循環学会評議員

  • 2018
    -
    Present

    日本ヘリコバクター学会代議員